STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Taysha (TSHA) Form 144 Filed for 19,604 RSU Shares via Maxim Group

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Taysha Gene Therapies insider notice to sell 19,604 shares via Maxim Group under Rule 144. The filing reports a proposed sale of 19,604 shares of common stock with an aggregate market value of $56,263.48 based on the filer’s information. The shares represent vested RSU awards acquired and settled in stock on 08/21/2025; the stated consideration for those awards was the reporting person’s continued service as an employee. The filing lists total outstanding shares of 272,794,885 and identifies Nasdaq as the exchange for the approximate sale date of 08/21/2025. No other sales in the past three months were reported.

Positive

  • Transaction disclosed under Rule 144, indicating compliance with resale reporting requirements
  • Shares originated from vested RSU awards, and the filing states the consideration (continued service) clearly
  • Broker identified (Maxim Group LLC), providing execution transparency

Negative

  • None.

Insights

TL;DR: Routine Form 144 disclosure of a small, post-vest insider sale; no material change to capitalization.

The filing documents a proposed sale of 19,604 shares, derived from vested RSUs settled in stock on 08/21/2025. At an aggregate market value of $56,263.48 against 272,794,885 shares outstanding, the transaction is immaterial to overall capitalization. The use of a broker (Maxim Group LLC) and the Rule 144 notice are consistent with standard compliance for restricted securities becoming eligible for public resale.

TL;DR: Disclosure follows standard insider-selling procedures; no governance red flags visible from this notice.

The form states the shares were awarded as RSUs and settled upon vesting with consideration being continued employment, and the filer affirms lack of undisclosed material information. The filing includes broker details and sale timing under Rule 144, matching expected governance and disclosure practices for an employee post-vesting sale.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the TSHA Form 144 disclose about the insider sale?

The filing discloses a proposed sale of 19,604 common shares with an aggregate market value of $56,263.48, to be executed approximately on 08/21/2025 via Maxim Group LLC on Nasdaq.

What is the origin of the shares being sold in the TSHA Form 144?

The shares were acquired as a vested RSU award settled in stock on 08/21/2025; the stated consideration was the reporting person’s continued employment.

How large is the proposed sale relative to TSHA's outstanding shares?

The filing reports 272,794,885 shares outstanding; the proposed sale of 19,604 shares is immaterial relative to that total.

Were any other securities of TSHA sold by the reporting person in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

Does the Form 144 indicate any undisclosed material information about TSHA?

By signing, the reporting person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Taysha Gene Therapies, Inc.

NASDAQ:TSHA

TSHA Rankings

TSHA Latest News

TSHA Latest SEC Filings

TSHA Stock Data

1.33B
243.67M
11.15%
94.76%
14.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
DALLAS